Scientists found no improvement in the recovery or death rate of patients given the drug combo.
The practice complicates getting meds during a time when it's already difficult.
The FDA expanded approval of ViiV Healthcare's Dovato, making it available to HIV-positive people not new to treatment.
Researchers advise proceeding with caution, though, as the treatment may interfere with the body's ability to fight fungal infections.
A survey from the World Health Organization found dozens of countries face a "critically low" stockpile of live-saving pills.
ViiV Healthcare's Rukobia will treat HIV-positive people dealing with drug resistance or intolerance.
A sweeping study found HIV-positive people adhering to their regimens are less at risk of serious repercussions from COVID-19.
